
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is viewed positively because 3Q26 results showed clear commercial momentum, with diluted EPS of $1.01 on revenue of $340.5M versus estimates of $0.79 and $336.4M, while management kept 2026 revenue guidance at $1.1B-$1.2B, implying about 51% growth at the midpoint. Lifyorli is scaling rapidly, reaching $91.4M in its second full quarter with over 2,300 patients started and more than 1,700 prescribers, while Korlym still rose 19% to $249.1M despite generic competition, suggesting the franchise can absorb pricing pressure through volume. The outlook is further supported by relacorilant’s advancing regulatory path, including a positive CHMP opinion on September 18, 2026 and a potential resubmission for Cushing’s syndrome, which could add another catalyst to a pipeline already aimed at multiple high-value indications.
Bears say
Corcept Therapeutics is facing a clouded international growth outlook because Most Favored Nation pricing makes the launch case beyond the U.S. difficult to underwrite, especially in Europe. The company has not yet committed to a European launch strategy, and the author excludes non-U.S. Lifyorli revenues from valuation because MFN pricing may pressure pricing, uptake, and economics. This raises reliance on the U.S. market alone, limiting near-term upside even though peer launches have shown an ex-U.S. market can exist, but under more favorable timing than the May 12, 2025 MFN announcement.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Corcept Therapeutics (CORT) Forecast
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares